SEGs in MA-K reveal that MA-K has strong clinical relevance with human aggressive DLBCL and onco-ribosomes, and others, such as CD52 and SSPN, are identified as promising prognostic biomarkers in human DLBCL. Here, CD52 is linked to diffuse large B-cell lymphoma.